These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
186 related items for PubMed ID: 32464217
1. CRISPR/Cas9-mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1. Zheng R, Li Y, Wang L, Fang X, Zhang J, He L, Yang L, Li D, Geng H. Kidney Int; 2020 Oct; 98(4):947-957. PubMed ID: 32464217 [Abstract] [Full Text] [Related]
2. Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene. Li Y, Zheng R, Xu G, Huang Y, Li Y, Li D, Geng H. Am J Physiol Renal Physiol; 2021 Mar 01; 320(3):F475-F484. PubMed ID: 33491567 [Abstract] [Full Text] [Related]
3. Generation of a Primary Hyperoxaluria Type 1 Disease Model Via CRISPR/Cas9 System in Rats. Zheng R, Fang X, He L, Shao Y, Guo N, Wang L, Liu M, Li D, Geng H. Curr Mol Med; 2018 Mar 01; 18(7):436-447. PubMed ID: 30539697 [Abstract] [Full Text] [Related]
4. In vivo base editing rescues primary hyperoxaluria type 1 in rats. Chen Z, Zhang D, Zheng R, Yang L, Huo Y, Zhang D, Fang X, Li Y, Xu G, Li D, Geng H. Kidney Int; 2024 Mar 01; 105(3):496-507. PubMed ID: 38142039 [Abstract] [Full Text] [Related]
5. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology. Estève J, Blouin JM, Lalanne M, Azzi-Martin L, Dubus P, Bidet A, Harambat J, Llanas B, Moranvillier I, Bedel A, Moreau-Gaudry F, Richard E. Biochem Biophys Res Commun; 2019 Oct 01; 517(4):677-683. PubMed ID: 31402115 [Abstract] [Full Text] [Related]
13. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1. Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, Chen D, Shui X, Saxena U, Cyr WA, Shah A, Nazef N, Wang W, Abrams M, Dudek H, Salido E, Brown BD, Lai C. Mol Ther; 2016 Apr 01; 24(4):770-8. PubMed ID: 26758691 [Abstract] [Full Text] [Related]
14. Differential expression of liver and kidney proteins in a mouse model for primary hyperoxaluria type I. Hernández-Fernaud JR, Salido E. FEBS J; 2010 Nov 01; 277(22):4766-74. PubMed ID: 20977670 [Abstract] [Full Text] [Related]
15. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1. Zheng R, Fang X, Chen X, Huang Y, Xu G, He L, Li Y, Niu X, Yang L, Wang L, Li D, Geng H. Clin Transl Med; 2020 Dec 01; 10(8):e261. PubMed ID: 33377632 [Abstract] [Full Text] [Related]
16. [From gene to disease; primary hyperoxaluria type I caused by mutations in the AGXT gene]. van Woerden CS, Groothof JW, Wanders RJ, Waterham HR, Wijburg FR. Ned Tijdschr Geneeskd; 2006 Jul 29; 150(30):1669-72. PubMed ID: 16922352 [Abstract] [Full Text] [Related]
17. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, Haslett P, Fitzgerald K, Holmes RP, Erbe D, Querbes W, Knight J. J Am Soc Nephrol; 2017 Feb 29; 28(2):494-503. PubMed ID: 27432743 [Abstract] [Full Text] [Related]